Flagship Pioneering, a scientific innovation engine for transformative platforms and products, today announced a research program under its strategic collaboration with Pfizer whereby Flagship-founded ...

Tom Bowen is a senior editor who loves adventure games and RPGs. He's been playing video games for several decades now and writing about them professionally since 2020. Although he dabbles in news and ...

This article first appeared on GuruFocus. Pfizer (NYSE:PFE) shares slid about 5% on Tuesday morning after the company lowered its earnings and revenue forecasts for 2026. The pharmaceutical giant now ...

The therapy YP05002 is part of the GLP-1 agonist class of drugs and is currently in early-stage development. Sign up here. Under the terms of the agreement, YaoPharma will complete the ongoing ...

Pfizer remains a compelling bargain, supported by a strong dividend yield and undervalued financial metrics, despite post-pandemic headwinds. PFE's acquisition of Metsera positions it for growth in ...

Pfizer’s mRNA flu vaccine outperformed the standard flu shot in a Phase 3 clinical trial, according to results published Wednesday in the New England Journal of Medicine. The vaccine uses the same ...

Deal marks Pfizer's re-entry into obesity treatment market Pfizer shares rise 1.4%, Novo Nordisk falls 1.3% Metsera candidate MET-097i advances to late-stage trials The greenlight from Metsera's ...

Signed, sealed and delivered, Metsera is finally Pfizer’s. Pfizer has completed its acquisition of the obesity biotech, capping a whirlwind two weeks in which rival pharma Novo Nordisk attempted to ...

The announcement of the deal signaled an end to the bidding war for Metsera between Pfizer and Novo Nordisk, the Danish maker of Ozempic and Wegovy. By Francesca Regalado The obesity drug developer ...

Pfizer's Q3 earnings fell, but the company still raised its full-year earnings guidance. Major cost reductions remain on track, which should significantly boost the drugmaker's bottom line. Pfizer's ...

Pfizer has axed 11 programs including two pipeline assets from its $43 billion Seagen acquisition, work on a BioNTech-partnered mRNA vaccine and a midstage metabolic dysfunction-associated ...

Novo Nordisk has launched a rival bid for U.S. obesity biotech firm Metsera, directly challenging an existing offer from Pfizer. The move, announced Thursday, escalates the competition between the two ...